Virologic Failure / Treatment Failure

Low Prevalence of Darunavir (Prezista) Resistance Mutations among Patients Who Experienced Treatment Failure with Other Protease Inhibitors - 10/19/07

Most Patients with Highly Drug-resistant HIV Treated with an Incompletely Suppressive Regimen Maintain Durable Immunological and Virological Responses despite Acquiring New Resistant Mutations - 10/05/07

After 4 Years of Viral Suppression with HAART, HIV Rebound Rates in Patients with Multiple Prior Treatment Failures Resemble Those in Individuals with No Prior Failure    - 7/07/07

Predictors of Antiretroviral Treatment Failure in an Urban HIV Clinic  1/19/07

Alcohol Use as a Risk Factor for Poor Adherence and Treatment Failure  1/12/07

Immune Reconstitution and Predictors of Virologic Failure in Adolescents Initiating HAART - 3/21/06

Is There a Future for Structured Treatment Interruption in HIV Patients Failing on HAART? - 9/28/05

Non European HIV Patients on HAART in a Dutch Cohort Show Increased Risk of Early Virological Failure - 9/23/05

High Rate of Virological Failure during Once-daily Therapy with Tenofovir + Didanosine 250mg + Efavirenz in Treatment-naive Patients - 8/08/05

Quadruple Nucleoside/tide Regimen of Trizivir + Tenofovir Is Effective Following Early Virologic Failure on an Initial Regimen Containing a Thymidine Analog + Lamivudine + a PI or NNRTI - 8/08/05

Adverse Events are the Main Cause of Treatment Failure in a Multicentre Trial in Naïve Patients, comparing Zidovudine/Lamivudine vs Stavudine/Didanosine, plus Efavirenz, Nevirapine or Indinavir/Ritonavir - 8/08/05

NIH Issues Short Update to HIV/AIDS Treatment Guidelines - 7/18/05

The Evaluation of Efficacy Endpoints: Discordant Conclusions from Clinical Trials of HIV - 7/13/05

Efficacy and Tolerability of a NRTI-sparing Combination of Lopinavir/Ritonavir and Efavirenz - 6/29/05

Multiple Drug Class-wide Resistance Is Associated with Poorer Survival after Treatment Failure - 6/22/05

Drug Resistance More Likely in NNRTI plus NRTI Regimens Compared with Ritonavir-boosted Protease Inhibitors - 4/25/05

Gender Differences in Clinical Progression of HIV Positive Individuals During Long-term HAART - 4/22/05

Use of Lopinavir/Ritonavir in HIV-infected Patients Failing First-line Protease Inhibitor-based HAART - 4/20/05

High Virological Failure Rate in Patients Switching to a Regimen with Two Nucleoside Reverse Transcriptase Inhibitors Plus Tenofovir - 4/11/05

Possible Explanation for CD4+ Cell Decline in HIV Patients with Complete Virus Suppression Taking Tenofovir and Didanosine - 4/08/05

Viral Rebound in Patients on First-line, PI-containing HAART Suggests a Lack of Adherence Rather Than the Selection of Resistant Variants - 4/04/05

In Patients with AIDS and CMV Positive, Detection of CMV Viremia with Plasma CMV DNA PCR Is Predictive of Death - 4/01/05

First-line Therapy with Efavirenz or Nevirapine is Effective in Patients with Advanced HIV Infection, and the Incidence of Rash in the Nevirapine Group Is Significantly Higher in Women with Higher CD4 Counts - 3/21/05

HIV RNA Decline within the First 2 Weeks of Treatment Is Comparable for Nevirapine, Efavirenz, or Both Drugs Combined and Does Not Predict Long-term Virologic Efficacy - 3/21/05

T-1249 Retains Potent Antiretroviral Activity in Patients with Virological Failure While on Enfuvirtide-containing Regimen   - 3/14/05

A New Triple Nucleoside Analogue Regimen Produces a Rapid, Durable HIV RNA Decrease with a Good Immunologic Response and a Good Safety Profile - 3/04/05

Efavirenz with Two Nucleoside Analogs Is Superior for Regimen Simplification  - 2/28/05

A Prospective, Randomized Trial of Structured Treatment Interruption for Patients with Chronic HIV - 2/02/05

Combining Fosamprenavir with Lopinavir/Ritonavir Substantially Reduces Amprenavir and Lopinavir Exposure: ACTG Protocol A5143 Results - 1/31/05

Alternation of Antiretroviral Drug Regimens for HIV Infection: Efficacy, Safety and Tolerability at Week 96 of the Swatch Study - 1/26/05

Treatment Interruption Fails to Yield a Clinically Significant Benefit - 1/19/05

Treatment Interruptions in Chronic HIV Infection - 1/19/05

Tenofovir, Lamivudine and Zidovudine Combination Therapy Results in Surprisingly Low Rate of Treatment Failure - 1/14/05

Use of African Herbal Medicines May Result in Bidirectional Drug Interactions and Put Patients at Risk of Treatment Failure, Viral Resistance or Drug Toxicity - 1/14/05

Abacavir/Lamivudine/Zidovudine + Tenofovir in Subjects with Early Virologic Failure on an Initial Regimen of Zidovudine or Stavudine + Lamivudine and a Protease Inhibitor or NNRTI - 11/29/04

Early Virologic Failure with Combination of Didanosine/Tenofovir Plus Either Efavirenz or Nevirapine - 11/17/04

Risk of Failure and Resistance at 6 Years - 11/19/04

Treatment Strategies Analyzed at HIV Meeting in Glasgow, Scotland - 11/17/04

Genotypic and Phenotypic Resistance Observations Among Patients with Viremia While on Lopinavir/Ritonavir "Monotherapy"  - 11/03/04

Predictors of Selection of K65R Mutation: Tenofovir Use and Lack of Thymidine Analogue Mutations  - 10/18/04

Long-term Virological Effect of HAART on Cerebrospinal Fluid and Relationship with Genotypic Resistance  - 10/18/04

Rapid HIV Decay in HAART-experienced Children After Starting Mega-HAART - 10/18/04

GENOPHAR: A Randomized Study of Plasma Drug Measurements in Association with Genotypic Resistance Testing and Expert Advice to Optimize Therapy  - 09/24/04

Analysis of Failure Rates in a Study of Resistance Profiles and Adherence in Three Different HAART Regimens  - 09/24/04

Drug Resistance in Subjects with Advanced HIV Infection in Whom Antiretroviral Combination Therapy Is Failing  - 08/18/04

Nevirapine-containing Regimens in Treatment-naïve HIV Patients with CD4 Cell Counts of 200 or Less  - 08/09/04

Evolution of Genotypic and Phenotypic Resistance to Enfuvirtide in HIV Patients Experiencing Prolonged Virologic Failure - 07/26/04

HIV Therapy After Treatment Interruption in Patients with Multiple Failure and More Than 200 CD4+ T Cells - 07/30/04

Virological and Immunological Impact of Withdrawal of NNRTI in HIV Patients with Multiple Treatment Failures - 06/25/04

The Reverse Transcriptase (RT) Mutation V118I is Associated with Virologic Failure on Abacavir-based Treatment - 06/25/04

Patients with a High Pre-HAART CD4+ Cell Count Are at  Increased Risk of Immunological Failure - 06/18/04

Effectiveness of Antiretroviral Therapy after Protease Inhibitor Failure  - 05/21/04

Persistent HIV Viremia Fosters Immunologic Harm and Viral Evolution  - 05/21/04

Rapid Clearance of HIV in Plasma after Peak Viremia Is Associated with Lower Viral Set Point, Prolonged Virus Suppression before Loss of Virologic Control and Decreased Risk of AIDS - 5/10/04

The Triple Nucleoside Combination of Abacavir, Zidovudine, and Lamivudine Proves "Virologically Inferior" to a Non Nucleoside Efavirenz- based Regimen in HIV Treatment-naïve Patients - 04/30/04

Treatment of HIV/AIDS in Patients Failing Their First HAART Regimen - 04/28/04

Predictors of Virologic Failure and Resistance in HIV Patients Treated with NNRTI Therapy - 4/21/04

Sex-Based Differences in Saquinavir Pharmacology and Virologic Response in ACTG Study 359 - 3/29/04

Does Use of Resistance Testing Improve Long-term Virologic Outcomes in HIV Patients? - 3/03/04

CD38 Expression Predicts Therapeutic Virologic Failure in HIV Positive Children - 3/03/04

Unexpected CD4 Cell-count Decline in Patients Receiving ddI- and Tenofovir-based Regimens Despite Undetectable Viral Load - 2/25/04